NASDAQ:IMRN Immuron Q2 2026 Earnings Results & Report $0.90 +0.05 (+5.86%) Closing price 11/20/2026 03:49 PM EasternExtended Trading$0.83 -0.07 (-7.54%) As of 11/20/2026 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immuron reported Q2 2026 earnings on February 25, 2026. The company reported EPS of -$0.0950, while revenue was $1.40 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateFebruary 25, 2026TimeBefore Market Opens Immuron EPS ResultsActual EPS-$0.0950Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuron Revenue ResultsActual Revenue$1.40 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Immuron Q2 2026 Earnings FAQ Did Immuron beat earnings estimates for Q2 2026? Immuron (NASDAQ:IMRN) reported earnings of -$0.0950 per share for Q2 2026. The report was announced on Wednesday, February 25, 2026. What was Immuron's revenue for Q2 2026? Immuron reported revenue of $1.40 million for Q2 2026. Immuron Earnings HeadlinesImmuron Publishes CEO Address and Annual General Meeting ResultsNovember 18, 2026 | tipranks.comImmuron Engages LifeSci Capital for Strategic InitiativesNovember 10, 2026 | tipranks.comWhoops! I wasn’t supposed to share this with you yetTraders have paid as much as $500 for technology like this. Thomas Wood of Base Camp Trading is offering his proprietary Snapback Indicator for just $7. There is no subscription and no recurring charge, and it's yours for life. The indicator is designed to help identify potential market turning points, showing when it may be time to buy, sell, or go short.November 22 at 1:00 AM | Base Camp Trading (Ad)Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic InitiativesNovember 10, 2026 | globenewswire.comEmerging Growth Research Reports Continued Revenue Growth at ImmuronNovember 5, 2026 | finance.yahoo.comImmuron CEO to showcase infectious-disease portfolio at Emerging Growth ConferenceOctober 28, 2026 | tipranks.comSee More Immuron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immuron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuron and other key companies, straight to your email. Email Address About ImmuronImmuron (NASDAQ:IMRN) Limited is an Australian biopharmaceutical company that develops and commercializes oral antibody-based products. Its approach uses targeted antibodies intended to bind pathogens or other biological targets in the gastrointestinal tract. The company’s principal commercial product is Travelan, an oral product designed to help prevent travelers’ diarrhea. Immuron also develops investigational therapies for infectious and inflammatory conditions, including candidates focused on Clostridioides difficile infection and other gastrointestinal diseases. Based in Melbourne, Immuron serves customers in Australia and other markets through sales and distribution arrangements. Its activities span commercializing oral health products and advancing its therapeutic candidates through clinical development.View Immuron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20Keysight Technologies: The Tollbooth on the Technology SuperhighwayGrowing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?Bargain Hunting: Why Off-Price Retail Is WinningZscaler Got a Boost From Palo Alto, But Now It Has to Deliver.If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.